AIM ImmunoTech Inc.
9 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC (NCT05494697) | AIM ImmunoTech Inc. | 2026-06-01 |
| Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions (NCT05592418) | AIM ImmunoTech Inc. | 2023-06-30 |
Track AIM ImmunoTech Inc. automatically
Every clearance here is in the API, with alerts when new ones post.